

Role of Cystatin C in early detection of renal impairment in Pre-diabetics

Thesis

Submitted for partial fulfillment of
Master degree in Internal medicine

By

Nahla Nader Adly
M.B, B. Ch

Under Supervision of

Prof. Dr. / Salah EL Din Ahmed Abu Shelbaya

Professor of Internal Medicine and Endocrinology
Faculty of Medicine – Ain Shams University

Dr. / Rania Sayed Abd El- Baky

Assistant Professor of Internal Medicine and Endocrinology
Faculty of Medicine – Ain Shams University

Dr. / Maram Mohamed Maher Mahdy

Lecturer of Internal Medicine and Endocrinology
Faculty of Medicine – Ain Shams University

Faculty of Medicine
Ain Shams University
2014

Lastly, I shall never forget to thank my mother and my father for their great support not only through this work but also through my whole life and to thank my colleagues for their support.

Nahla Nader Adli Zaki



Acknowledgement

First of all, thanks to **Allah** the most merciful for giving me the strength to complete this work.

I wish to express my deepest thanks and respect for **Prof. Dr. Salah EL Din Ahmed Abu Shelbaya** Professor of Internal Medicine and Endocrinology, Faculty of Medicine, Ain Shams University, for his valuable supervision, guidance and kind advice throughout this work.

Also I wish to express my deep gratitude to **Asses. Prof. Dr. Rania Sayed Abd EL-Baky**, Asses. Prof of Internal Medicine and Endocrinology, Faculty of Medicine, Ain Shams University for her good support, continuous supervision and unlimited help during this work.

I also like to express my deepest gratitude to **Dr. Maram Mohamed Maher Mahdy**, Lecturer of Internal Medicine and Endocrinology, Faculty of Medicine, AinShams University for her continuous supervision, guidance, support and encouragement.

And **Dr. Magdy Abbas Abd El-Aziz**, Consultant of Biochemistry, Faculty of Medicine, AinShams University Hospital

List of Contents

Title	Page
List of tables	i
List of figures	ii
list of Abbreviations	iv
Introduction.....	1
Aim of the Work.....	3
Review of Literature	
○ Prediabetes.....	4
○ Cystatin C.....	50
○ Diabetic Nephropathy.....	69
Patients and Methods	106
Results	119
Discussion	134
Summary.....	142
Conclusion.....	146
Recommendations	147
References	148
Arabic summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Categories of increased risk for diabetes	8
Table (2):	World estimates of IGT (adjusted to the world population) by the IDF region:	12
Table (3):	Cystatin superfamily:	55
Table (4):	Definitions of Abnormal Albumin Excretion:	74
Table (5):	Pathology of Diabetic Nephropathy	87
Table (6):	Oral hypoglycemic agents	101
Table (7):	Comparison between group I (prediabetics) and group II (healthy volunteers) regarding the different variants using t-test	124
Table (8):	Correlation between serum cystatin C level and other parameters in group I (prediabetics) and correlation between serum cystatin C and other parameters in group II (healthy volunteers) using Pearson correlation	125
Table (9):	Correlation between serum cystatin C level and gender in group I (prediabetics) and group II (healthy volunteers)	126
Table (10):	Correlation between serum cystatin C level and other study parameters in the two groups using Pearson correlation	127
Table (11):	Correlation between eGFR and other study parameters in the two groups using Pearson correlation	128
Table (12):	Multiple logistic regression analysis showing correlations between cystatin C and different parameters in both groups	129
Table (13):	Multiple logistic regression analysis showing correlations between eGFR and different parameters in both groups	130

List of Figures

Fig. No	Title	Page
Figure (1):	Global projections for impaired glucose tolerance (IGT) for 2007 and 2025 (in millions of individuals) and projected per cent increase from 2007 to 2025	6
Figure (2):	Fasting and 2-hour postload glucose, Homeostasis model assessment insulin sensitivity (HOMA2-%S) and HOMA β -cell function (HOMA2-%B)	22
Figure (3):	Metabolic Pathways Underlying Pre-Diabetes and Metabolic Syndrome.....	28
Figure (4):	Relative risk of CVD in normoglycemia, prediabetes and type 2 diabetes	38
Figure (5):	Features of insulin signal transduction pathways in skeletal muscle and vascular tissue	43
Figure (6):	Structure of human cystatin C (HCC).....	56
Figure (7):	The molecular mechanism involved in induction and progression of diabetic nephropathy	77
Figure (8):	Schematic diagram of the interrelationship of the glomerulus, the podocyte, the pedicels, and the basal laminae	81
Figure (9):	Mediators of podocyte injury in DKD.....	83
Figure (10):	Light microscopy photographs of glomeruli in sequential kidney biopsies performed at baseline and after 5 and 10 years of follow-up in a patient with longstanding normoalbuminuric type 1 diabetes with progressive mesangial expansion and kidney function deterioration.....	89

List of Figures (Cont...)

Fig. No	Title	Page
Figure (11):	Electron microscopy photographs of mesangial area in a normal control subject and in a patient with type 1 diabetes.....	90
Figure (12):	Light microscopy photographs of glomeruli from type 1 (A) and type 2 (B through D) diabetic patients	92
Figure (13):	Typical Standard Curve for Human Cystatin C ELISA.	117
Figure (14):	Comparison between the studied groups regarding serum cystatin C level.	131
Figure (15):	Correlation between serum cystatin C level and fasting blood glucose.....	131
Figure (16):	Correlation between serum cystatin C level and glycated haemoglobin (HbA1c)	132
Figure (17):	Correlation between serum cystatin C level and 1hr postprandial blood glucose.....	132
Figure (18):	Correlation between serum cystatin C level and 2hr postprandial blood glucose.....	133
Figure (19):	Correlation between serum cystatin C level and eGFR.....	133

List of Abbreviation

Abb.	Full term
1-hrPP	1 hour postprandial
2-hrPP	2 hours postprandial
AACE	American association of clinical endocrinologists
ACE	Angiotensin converting enzyme
ACR.....	Albumin/creatinine ratio
ADA	American Diabetes Association
AER	Albumin excretion rate
ARBs	Angiotensin II receptor blockers
BM.....	Basement membrane
BMI.....	Body mass index
BP	Blood pressure
CABG	Coronary aretery bypass grafting
CAD.....	Coronary artery disease
CHD.....	Coronary heart disease
CKD.....	Chronic kidney disease
CSF	Cerebrospinal fluid
CST3.....	Cystatin C
CST9.....	Cystatin 9
CVD.....	Cardiovascular disease
Cys-C.....	Cystatin C
DCCT	Diabetes Control and Complications Trial
DECODE.....	Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe
DKD	Diabetic kidney disease
DN	Diabetic nephropathy
DPP.....	Diabetes Prevention Program
DPP4 inhibitors	Dipeptidyl peptidase 4 inhibitor
DRIs.....	Direct renin inhibitors
eGFR.....	Estimated glomerular filtration rate
EGP.....	Endogenous glucose production
eNOS	endothelial nitric oxide synthase
ESRD	End Stage Renal Disease

List of Abbreviation (Cont...)

Abb.	Full term
FBG	Fasting blood glucose
FFA.....	Free Fatty Acids
GBM	Glomerular basement membrane
GDM.....	Gestational diabetes mellitus
GFR	Glomerular Filtration Rate
GLP-1	Glucagon-like peptide-1
GWAS	Genome-wide association study
HCC.....	Human cystatin C
HCCAA	hereditary cystatin C amyloid angiopathy
HDL.....	High Density Lipoprotein
HGO	Hepatic glucose output
HOMA	Homeostasis Model Assessment
ICAM-1	Intercellular adhesion molecule-1
IDF.....	International Diabetes Federation
IDNT.....	International dietetics and nutrition terminology
IFG.....	Impaired fasting glucose
IGT	Impaired glucose tolerance
IL-6	Interleukin 6
IR	Insulin resistance
IRF8.....	Interferon regulatory factor 8
JAK-STAT	Janus kinases-signal transducer and activator of transcription signaling
kDa	kilodalton
KDIGO	Kidney Disease:Improving Global Outcomes
KORA.....	Cooperative health research in the region of Augsburg
LDL	Low density lipoproteins
MAP- kinase.....	Mitogen-activated protein kinase
MCP-1	Monocyte chemoattractant protein-1
MDRD	Modification of Diet in Renal Disease
MMP-2	Matrix metalloproteinase-2

List of Abbreviation (Cont...)

Abb.	Full term
NADPH	Nicotinamide adenine dinucleotide phosphate oxidase
NDDG.....	National Diabetes Data Group
NF-kB	Nuclear factor Kappa-light-chain-enhancer of activated Bcells
NGT	Normal glucose tolerance
NHANES.....	National Health and Nutrition Examination Survey
NO	Nitric oxide
OGTT	Oral glucose tolerance test
PAI-1	Plasminogen activator inhibitor-1
PCI.....	Percutaneous coronary intervention
PI 3-kinase	Phosphatidylinositol 3-kinase
PK C	Protein kinase
PPAR- γ	Peroxisome proliferator-activated receptor gamma
PU.1	The macrophage transcription factor
RAS	Renin angiotensin system
RENAAL.....	Reduction in endpoints with angiotensin antagonist losartan
ROS	Reactive oxygen species
RR.....	Relative risk
sCr.....	Serum creatinine
SGLT2	Sodium-glucose co-transporter 2
SHARP	The Study of Heart and Renal Protection
SNPs	Single-nucleotide polymorphisms
T2DM	Type 2 Diabetes Mellitus
TBM	Tubular basement membrane
TG.....	Triglycerides
TGF	Transforming growth factor
TNF	Tumor necrosis factor
UAE.....	Urinary albumin excretion
UKPDS	The United Kingdom prospective diabetes study
VCAM 1	Vascular cell adhesion molecule 1
VEGF.....	Vascular endothelial growth factor
VLDL	Very low density lipoprotein
WHO.....	World Health Organization



INTRODUCTION

Pre-diabetes is an asymptomatic condition not associated with functional impairment that mostly presents prior to the individual developing type 2 diabetes (*De veegt et al., 2001*). It consists of impaired fasting glucose (IFG) (100-125 mg/dl), impaired glucose tolerance (IGT) (140-199 mg/dl), or both (*Genuth et al., 2008*).

5-10 % of people per year with pre-diabetes will progress to diabetes, with the same proportion converting back to normoglycaemia. Prevalence of pre-diabetes is increasing worldwide and experts have projected that more than 470 million people will have pre-diabetes by 2030. pre-diabetes is associated with the simultaneous presence of insulin resistance and beta cell dysfunction-abnormalities that start before glucose changes are detectable (*Tabák et al., 2012*).

Risk factors for developing diabetes mellitus include: age; ethnicity; weight; first-degree relative with type 2 diabetes; low birthweight and sedentary lifestyle. Certain comorbidities increase the risk of type 2 diabetes, these include: cardiovascular and cerebrovascular disease; polycystic ovary syndrome; a history of gestational diabetes; and mental health problems (*Savill, 2012*).



Cystatin C, a cysteine protease inhibitors freely filtered by the renal glomeruli, metabolised by the proximal tubule, has been identified as an early marker of renal failure. Cystatin C is produced at a constant rate by nucleated cells and released into the bloodstream with a half-life of about 2 hours. Its concentration is almost totally dependent on the glomerular filtration rate (*Willems et al., 2009*).

Cystatin C may detect mild-to-moderate decreases in GFR that are not evident with serum creatinine-based measurements. Some studies suggest that CysC–GFR was better than creatinine-based estimates of GFR at GFR levels >60 mL/min/1.73 m² (CKD stages 1 and 2). In addition, CysC–GFR appeared to be better correlated with microalbuminuria, while MDRD and CG creatinine estimates of GFR tend to reflect only proteinuria (*Yang et al., 2007*).



AIM OF THE WORK

The aim is to study the role of Cystatin C in early detection of renal affection in the pre-diabetics.

PREDIABETES

Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Cutoff glycemic levels defining diabetes are based on the observed association between certain glucose levels and a dramatic increase in the prevalence of microvascular complications considered specific for hyperglycemia (retinopathy and nephropathy) (*Martin and Michael, 2011*).

In 1979, the National Diabetes Data Group (NDDG) first introduced the concept of a metabolic state intermediate between normal glucose homeostasis and diabetes, called glucose intolerance. Individuals with glucose intolerance did not meet the criteria for being diagnosed with diabetes but had glucose levels higher than those considered normal (*Diabetes Prevention Program Research Group, 2007*).

Although Type 2 diabetes is a globally growing public health concern, a much larger segment of the world's population is actually diagnosed with pre diabetes, which is defined as having blood glucose concentrations higher than normal, and not yet meeting the definition of diabetes per se. Based on the World Health Organization (WHO), individuals with pre-diabetes have impaired fasting glucose concentration (IFG) ranging between 110 mg/dl and 126 mg/dl, and/or impaired glucose tolerance (IGT), defined as plasma glucose

concentration 2 h post 75 g oral glucose load, ranging between 140 mg/dl and 199 mg/dl (*World Health Organization, 2006*).

The American Diabetes Association (ADA), uses the same WHO definition for the post-load threshold values for impaired glucose tolerance however a lower cutoff value for impaired fasting glucose is used and it ranges between 100 and 125 mg/dl. Furthermore, the ADA stated that glycated hemoglobin (HbA1c) between 5.7 and 6.4% can also be used for diagnosing pre diabetes. It is important to note that the ADA and the WHO recognize that HbA1c level $\geq 6.5\%$ is indicative of diabetes (*American Diabetes Association, 2013*).

Progression from prediabetes to diabetes:

"Prediabetes" is the term used for individuals with IFG and/or IGT, indicating the relatively high risk for the future development of diabetes. IFG and IGT should not be viewed as clinical entities in their own right but rather risk factors for diabetes and cardiovascular disease (CVD). IFG and IGT are associated with obesity (especially abdominal or visceral obesity), dyslipidemia with high triglycerides and/or low HDL cholesterol, and hypertension (*American Diabetes Association, 2014*).

As per the International Diabetes Federation, 382 million people worldwide, or 8.3% of adults, were found to have diabetes in the year 2013 and by the year 2035 this will rise to